Highest-materiality recent filing
Aclarion stockholders elect seven directors, ratify auditor, approve equity plan amendment
All seven director nominees elected; votes for ranged from 468,385 to 533,055; broker non-votes 841,750.
Aclarion authorizes $2.5 million share repurchase program over 12 months
Board authorized repurchase of up to $2.5M in common stock over next 12 months.
Aclarion adopts one-year stockholder rights plan with 10% trigger
Board unanimously adopted Rights Plan effective March 19, 2026, expiring March 18, 2027.
Aclarion closes $10.4M equity offering, reports $21.6M cash, zero debt, runway into 2028
Closed $10.4M common-stock-only offering at $5.18/share; includes 200,000 shares and pre-funded warrants for 1.8M shares.
Aclarion raises ~$10.36M via registered direct offering of common stock and pre-funded warrants
200,000 shares at $5.18 each; pre-funded warrants for 1.8M shares at $0.00001 exercise price.
Aclarion raises ~$2.5M via registered direct offering of stock and pre-funded warrants
Issued 64,000 common shares and 236,000 pre-funded warrants at $8.36/share; gross proceeds ~$2.5M.
Aclarion appoints Greg Gould as CFO; John Lorbiecki retires
Gregory A. Gould appointed CFO effective September 1, 2025, succeeding retiring John Lorbiecki.
Aclarion shareholders approve reverse stock split, reject equity plan amendment
All seven director nominees elected with 47,374 to 51,347 votes for; broker non-votes of 200,431.
Aclarion adjourns annual meeting to July 21 to solicit additional votes
Annual meeting convened then adjourned without business on July 7, 2025.
CFO John Lorbiecki to retire; replacement search underway, expected by Q3 2025
John Lorbiecki notified retirement on June 16, 2025; will stay to transition duties.
Cash on hand ~$14.6M as of Apr 9 2025 10-K; runway into Q3 2026; zero debt, no preferred shares, no near-term warrant overhang.
Aclarion effectuates 1-for-27 reverse stock split; shares reduce from ~15.72M to ~582K
Reverse stock split at 1-for-27 ratio effective 5:00 p.m. ET on March 27, 2025; split-adjusted trading commenced March 28.
Aclarion reports $15.2M cash, regains Nasdaq equity compliance; 87% of Series B warrants exercised
Current cash balance ~$15.2M; company in compliance with Nasdaq stockholders' equity rule of $2.5M minimum.
Aclarion stockholders approve share issuance and authorized share increase at special meeting
Issuance Proposal: 3,750,201 for, 383,538 against, 6,225 abstentions; approved.
Aclarion adjourns special meeting to March 5 to solicit additional votes
Special Meeting convened Feb 28, 2025, adjourned without transacting any business.
Aclarion prices $4.7M registered direct offering of 506,803 shares at $9.25 each
Gross proceeds ~$4.7M; 506,803 shares at $9.25/share; closing expected Jan 31, 2025.
Aclarion effects 1-for-335 reverse stock split; regains Nasdaq equity compliance
Reverse stock split effective Jan 29, 2025 at 1:335 ratio; shares reduced from ~169.4M to ~500,000.
Net proceeds of ~$13.3M from offering of 100K shares, ~144M pre-funded warrants, and Series A & B warrants.
Aclarion prices registered direct offering of 3.38M shares at $0.142/share for ~$480K gross proceeds
Pricing: 3,380,276 shares at $0.142 per share; gross proceeds ~$480,000 before fees and expenses.
Aclarion shareholders approve all 7 proposals at 2024 annual meeting
Seven directors elected, each receiving >1.1M votes for (no broker-non-votes excluded).
Aclarion terminates $10M ATM sales agreement with Ascendiant Capital Markets, effective Jan 3
Terminated At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC on January 3, 2025.
Equity line expiration extended from Dec 31, 2024 to Dec 31, 2025.
Aclarion receives Nasdaq delisting notice for bid price; hearing held Oct 10
Received Oct 8 notice of non-compliance with $1 bid price requirement for Nasdaq Capital Market.
Aclarion raises $1.0M via Series C convertible preferred stock and warrants
Gross proceeds of $1.0M from sale of 1,000 shares of Series C Preferred Stock at $1,000/share, convertible at $0.1759 per share.
Aclarion enters ATM equity agreement to sell up to $10M common stock, initial $1.075M
ATM issuance sales agreement with Ascendiant Capital Markets for up to $10M of common stock.
Aclarion stockholders approve reverse stock split of 1:5 to 1:50
Stockholders approved reverse split with 2,050,165 For, 1,133,449 Against, 583,616 Abstain.
Aclarion raises $290k via 1M share offering at $0.29; also issues warrants for 400k shares
Issued 1,000,000 shares at $0.29/share for gross proceeds of $290,000.
Aclarion receives Nasdaq delisting notice for stockholders' equity shortfall
Nasdaq notified Aclarion it fails minimum $2.5M stockholders' equity requirement, reporting $1.64M as of June 30, 2024.
Aclarion exchanges $930K of near-maturing notes for Series B Preferred convertible at $0.234/share
Exchanged $930,000 of principal and accrued interest on notes due Sept 2024 for 930 Series B Preferred shares at $1,000 each.
Aclarion sells 400k shares at $0.29, raising $116k; may raise up to $29.68M more
Sold 400,000 shares of common stock at $0.29 per share for gross proceeds of $116,000.
Aclarion raises $116K via sale of 400K shares at $0.29 per share to institutional investor
Issued 400,000 shares of common stock at $0.29/share for gross proceeds of $116,000.
Aclarion gets first payer coverage for Nociscan from AXA in Greater London
AXA is the 2nd largest private medical insurer in the UK with ~30% market share and ~3M insured customers.
Aclarion amends bylaws to reduce stockholder meeting quorum from majority to one-third
Board adopted amendment on June 12, 2024; quorum reduced to holders of one-third of voting power from a majority.
Aclarion raises $304,500 via equity line, shares outstanding increase to 8.2M
Closed on $304,500 in new capital by selling 1.05M shares under existing equity line facility.
Aclarion receives Nasdaq notice of non-compliance with minimum bid price rule
Received Nasdaq notice on April 8, 2024 for failing minimum bid price of $1.00 per share over 30 consecutive business days.
Aclarion closes $3.0M public offering; believes it regains Nasdaq equity compliance
Closed public offering of 5,175,000 units at $0.58/unit; gross proceeds ~$3.0M before expenses.
Aclarion posts $4.9M net loss in FY2023; auditor flags going concern doubt
Net loss of $4.9M in FY2023 vs $7.1M in FY2022; revenue $75,404, up 25% from $60,444.
Aclarion exchanges ~$1.19M debt for 500k shares, boosting share count to 1.79M
From Jan 23–26, 2024, Aclarion entered exchange agreements with accredited investors to swap debt for equity.
Aclarion exchanges $157K of notes for 56K shares at $2.8101 per share
Exchanged $157,365.60 of principal and accrued interest on unsecured notes for 56,000 common shares at $2.8101/share.
Aclarion effectuates 1-for-16 reverse stock split; shares reduce to ~840K
Effective January 3, 2024, every 16 shares of common stock combined into 1 share; no fractional shares issued.
Seven directors elected with ~3.5M votes for each; broker non-votes ~1.63M.
Aclarion closes $250K unsecured note financing with 8% interest and warrants
Gross proceeds of $250,000 from accredited investors via unsecured non-convertible notes.
Aclarion enters $10M common stock purchase agreement with White Lion Capital
Up to $10M aggregate gross purchase of newly issued common stock at discounts of 85-95% of VWAP.
Aclarion updates investor deck; highlights CLARITY trial start Q4 2023 with 300 patients
CLARITY prospective randomized trial begins Q4 2023; 300 patients, 42-month timeline, Johns Hopkins anchor site.
Aclarion receives Nasdaq delisting notice for equity shortfall; appeals to hearings panel
Nasdaq staff determined to delist common stock on Aug 31, 2023 for failure to meet $2.5M stockholders' equity requirement.
Aclarion closes $750K second tranche of unsecured note financing; amends terms
Received $750K gross proceeds from second tranche; principal amount $862.5K (15% OID).
Aclarion regains Nasdaq compliance after late 10-Q; auditor resigns, Haynie & Company appointed
Filed Q2 2023 Form 10-Q on Aug 25; Nasdaq confirmed compliance with Listing Rule 5250(c)(1) on Aug 28.
Aclarion files delayed Q2 10-Q after Nasdaq notice; believes compliance regained
Received Nasdaq notice on August 23, 2023 for non-compliance with Listing Rule 5250(c)(1) due to late 10-Q.
Aclarion waives monthly interest on $1.44M notes, defers all interest to maturity
Waived monthly interest on $1.23M (Cavalry Fund) and $208K (WVP) unsecured non-convertible notes.
Aclarion receives Nasdaq notice for non-compliance with $1.00 minimum bid price requirement
Nasdaq notice dated Aug 4, 2023, due to closing bid price below $1.00 for 30 consecutive business days through Aug 3, 2023.
On June 16, 2025, John Lorbiecki notified Aclarion, Inc. of his intention to retire from his position as the Company’s Chief Financial Officer.
Max materiality 0.85 · Median 0.60 · Most common event other_material